α-Syn-SM / Innovative California Biosciences International - LARVOL DELTA

Journal of the American Academy of Neurology Publishes ProMIS Neurosciences’ Abstracts on Novel Antibody Candidates (GlobeNewswire, ProMIS Neurosciences Inc.) - "ProMIS Neurosciences, Inc....demonstrate the strength of its antibody programs for Parkinson’s disease/alpha-synuclein (a-syn) and amyotrophic lateral sclerosis (ALS)/TDP-43....The abstract...demonstrates the success of the ProMIS discovery platform in identifying disease-associated targets and generating antibodies against the toxic species of a-syn while preserving the healthy protein. The misfolded form of a-syn is implicated in the development of Parkinson’s disease, dementia with Lewy bodies (DLB) and multiple system atrophy (MSA).... Abstract reveals a family of antibodies reactive with a defined region of TDP-43 that becomes exposed on misfolded/aggregated, disease-associated TDP-43 but not on the properly folded healthy protein. Pathogenic TDP-43 is a recognized driver of ALS and frontotemporal lobar dementia (FTLD)."

Clinical • Preclinical